Developing new therapies for Non-Small Cell Lung Cancer using engineered aptamers
Official title: Molecular engineering and systematic evaluation of bispecific aptamers to develop potent and efficacious therapies for the immunomodulation of Non-Small Cell Lung Cancer
Funded at University of Missouri-Columbia · NIH-10918084 · Data updated 2026-11-12
This study is looking at new treatments for Non-Small Cell Lung Cancer that use special molecules to help your immune system fight the cancer more effectively, aiming to make the treatment work better and cause fewer side effects.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project start | August 21, 2023 |
| Project end | August 20, 2027 |
| Funding year | 2024 |
| Award (this year) | $34,658 |
| NIH project number | 5F30CA275349-02 |
| Project ID | NIH-10918084 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Non-Small Cell Lung Cancer who may not have responded well to existing therapies.
✕Less likely to help
Patients with other types of cancer or those who are not diagnosed with Non-Small Cell Lung Cancer may not receive any benefit from this research.
What this research studies
This research focuses on creating and testing bispecific aptamers, which are specialized molecules designed to target and modulate the immune response against Non-Small Cell Lung Cancer (NSCLC). By leveraging aptamer technology, the study aims to develop therapies that can effectively overcome challenges such as tumor resistance and side effects associated with current treatments. Patients may benefit from these therapies as they are designed to be more specific and less immunogenic than traditional antibodies, potentially leading to better outcomes with fewer adverse effects.
Why it matters
Potential benefit: If successful, this research could provide patients with more effective and safer treatment options for Non-Small Cell Lung Cancer.
How similar studies have gone: While the use of aptamers in cancer therapy is a promising area, this specific approach is relatively novel and has not been extensively tested in the context of NSCLC.
Where this research is happening
-
University of Missouri-Columbia
Columbia, United States Active
Researchers
- Principal investigator: Thomas, Brian J — University of Missouri-Columbia
- Study coordinator: Thomas, Brian J
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.